AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Orion Oyj

Report Publication Announcement Jul 17, 2019

3232_fs_2019-07-17_983e0b7a-b6be-4209-99db-1c114c74591f.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Disclosure 373390

Orion - Financial Calendar

Orion Corporation's financial reporting and Annual General Meeting in 2020

ORION CORPORATION STOCK EXCHANGE RELEASE 17 JULY 2019 at 11.00 a.m. EEST

Orion Corporation's financial reporting and Annual General Meeting in 2020

Orion Corporation will publish its Financial Statement Release 2019 on Wednesday, 5 February 2020.

The publication dates of the Interim Reports and the Half-Year Financial Report in 2020 are as follows:

Interim Report January-March 2020 Tuesday, 28 April 2020

Half-Year Financial Report January-June 2020 Friday, 17 July 2020

Interim Report January-September 2020 Wednesday, 21 October 2020

The Financial Statements and the Report of the Board of Directors for 2019 will be published on the Company's website at the latest in week 10/2020.

The Annual General Meeting is planned to be held on Wednesday, 25 March 2020 in Helsinki.

Orion's financial reports and related presentation material are available on the Group's website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases.

Orion Corporation

Timo Lappalainen

President and CEO
Olli Huotari

SVP, Corporate Functions

Contact person:

Terhi Ormio, Vice President, Communications

tel. +358 50 966 4646

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

Homepage: www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion’s net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

Talk to a Data Expert

Have a question? We'll get back to you promptly.